G.d. Searle & Company

Pfizer Corporation

Pharmacia Corporation

G.d. Searle LLC

Aziz Karim

Richard M Weier

Gilbert W Adelstein

James Carnegie Forbes

Ping Gao

Chung H Yen

Rajeev D Gokhale

Tugrul T Kararli

Martin John Griffin

Subhash Desai

James E Truelove

William J Marsheck

Kalidas Paul

James C Stolzenbach

Sandeep Nema

David J Zold

Andrew M Brugger

Fred Hassan

Ajit K Roy

Mark E Adams

Douglas J Schaaf

A pharmaceutical composition comprises, in powder form, (a) at least one water-soluble therapeutic agent selected from selective COX-2 inhibitory drugs and prodrugs and salts thereof, for example parecoxib sodium, in a therapeutically effective total amount constituting about 30% to about 90% by weight, (b) a parenterally acceptable buffering agent in an amount of about 5% to about 60% by weight, and optionally (c) other parenterally acceptable excipient ingredients in a total amount not greater than about 10% by weight, of the composition. The composition is reconstitutable in a parenterally acceptable solvent liquid to form an injectable solution. A lyophilization process is provided for preparation of such a composition.

Reconstitutable parenteral composition

Oral pharmaceutical formulation which improves the bioavailability of pharmaceuticals which are substantially water and oil insoluble is disclosed. In addition to the pharmaceutical, the formulation includes an emulsifier, an oil and an solubilizer. Alternatively, the formulation includes an aqueous solution of solubilizer.

Self-emulsifying drug delivery system

There is provided a method of rapidly relieving pain in a mammalian, preferably human, subject. The method comprises orally administering to the subject an effective pain-relieving amount of a composition comprising celecoxib formulated in such a way as to provide, when tested in fasting humans in accordance with standard pharmacokinetic practice, a blood plasma concentration profile of celecoxib in which a concentration of about 250 ng/ml is attained not later than about 30 minutes after oral administration.

Use of a celecoxib composition for fast pain relief

Pharmaceutical compositions containing potassium, sodium or Tris salt of oxaprozin as an active agent. The pharmaceutical compositions of the present invention are useful in eliminating or ameliorating pain and in the treatment of inflammation and inflammation associated disorders such as rheumatoid arthritis and osteoarthritis.

Potassium, sodium and tris oxaprozin salt pharmaceutical formulations

This invention encompasses novel 5-[1,1-diphenyl-3-(5-or 6-hydroxy-2-azabicyclo[2.2.2]oct-2-yl)propyl]-2-alkyl-1,3,4-oxadiazoles and their lower O-alkanoyl derivatives. These compounds are useful anti-diarrheal agents and also possess little or no analgesic activity.

5-(1,1-Diphenyl-3-(5- or

The preparation and valuable biological properties - especially diuretic activity - of 6.beta.,17-dihydroxy-7.alpha.-(lower alkoxy)carbonyl-3-oxo-17.alpha.-pregn-4-ene-21-carboxylic acid .gamma.-lactones and the corresponding hydroxy acids and salts thereof are disclosed.

6.beta.,17-Dihydroxy-7.alpha.-(lower

Growing community of inventors

Skokie, IL, United States of America

Aziz Karim